| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36089addd8e49e968b4c7e13c517dd1c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 |
| filingDate |
1992-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18ca9eef46363444af9ae7ea3c121447
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_627ec1e944ed81b1f9e621a2e7f62da8 |
| publicationDate |
1992-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0509598-A1 |
| titleOfInvention |
Use of ibopamine for the manufacture of a pharmaceutical composition for the treatment of glaucomatous optic neuropathy |
| abstract |
Use of Ibopamine, i.e. 4-[2-(methyl-amino)-ethyl]-1,2-phenylene ester of 2-methylpropanoic acid, or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a pharmaceutical composition for the treatment of glaucomatous optic neuropathy is described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03032969-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03032969-A3 |
| priorityDate |
1991-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |